{"id":2995,"date":"2019-05-17T12:45:00","date_gmt":"2019-05-17T12:45:00","guid":{"rendered":"http:\/\/www.irlab.se\/irlab-genomfor-aktiesplit\/"},"modified":"2019-05-17T12:45:00","modified_gmt":"2019-05-17T12:45:00","slug":"irlab-genomfor-aktiesplit","status":"publish","type":"post","link":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/","title":{"rendered":"IRLAB genomf\u00f6r aktiesplit"},"content":{"rendered":"<p><span>Sista dag f&ouml;r handel med aktier f&ouml;re uppdelningen &auml;r m&aring;ndagen den 27 maj 2019 och f&ouml;rsta dag f&ouml;r handel med aktier efter uppdelningen &auml;r tisdagen den 28 maj 2019. Detta inneb&auml;r att aktiekursen kommer att &aring;terspegla effekten av uppdelningen fr&aring;n och med den 28 maj 2019.<\/span><\/p>\n<p><span>Avst&auml;mningsdagen f&ouml;r genomf&ouml;rande av uppdelningen infaller onsdagen den 29 maj 2019 och aktierna som erh&aring;lls genom uppdelningen ber&auml;knas registreras p&aring; aktie&auml;garnas konton fredagen den 31 maj 2019 vilket &auml;r den f&ouml;rsta bankdagen efter avst&auml;mningsdagen.<\/span><\/p>\n<p><span>Den nya ISIN-koden kommer att vara SE0012675361 f&ouml;r aktierna av Serie A och<\/span> <span>SE0012675379 f&ouml;r aktierna av Serie B.<\/span><\/p>\n<p><span>Genom uppdelningen kommer antalet aktier i bolaget att &ouml;ka fr&aring;n sammanlagt 8&nbsp;099&nbsp;939, varav 8&nbsp;028&nbsp;388 aktier av Serie A och 71&nbsp;551 aktier av Serie B, till sammanlagt 40&nbsp;499&nbsp;695, varav 40&nbsp;141&nbsp;940 aktier av Serie A och 357&nbsp;755 aktier av Serie B. Villkoren f&ouml;r konvertering av aktier av Serie B till aktier av Serie A samt villkoren f&ouml;r utest&aring;ende teckningsoptioner har som en f&ouml;ljd av uppdelningen omr&auml;knats i enlighet med villkoren.<\/span><\/p>\n<p><span>Uppdelningen av bolagets aktier sker automatiskt via Euroclear Sweden AB och aktie&auml;gare beh&ouml;ver inte vidta n&aring;gra &aring;tg&auml;rder.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vid IRLAB Therapeutics AB:s \u00e5rsst\u00e4mma den 25 april 2019 beslutades om en uppdelning av bolagets aktie, en s\u00e5 kallad aktiesplit. De beslutade villkoren f\u00f6r aktiespliten \u00e4r en 5:1 uppdelning, d\u00e4r varje nuvarande aktie (1) delas upp i fem (5) aktier av samma slag. Datum f\u00f6r genomf\u00f6randet av uppdelningen har nu fastst\u00e4llts.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-2995","post","type-post","status-publish","format-standard","hentry","category-pressmeddelande-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB genomf\u00f6r aktiesplit - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB genomf\u00f6r aktiesplit - IRLAB\" \/>\n<meta property=\"og:description\" content=\"Vid IRLAB Therapeutics AB:s \u00e5rsst\u00e4mma den 25 april 2019 beslutades om en uppdelning av bolagets aktie, en s\u00e5 kallad aktiesplit. De beslutade villkoren f\u00f6r aktiespliten \u00e4r en 5:1 uppdelning, d\u00e4r varje nuvarande aktie (1) delas upp i fem (5) aktier av samma slag. Datum f\u00f6r genomf\u00f6randet av uppdelningen har nu fastst\u00e4llts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-17T12:45:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"IRLAB genomf\u00f6r aktiesplit\",\"datePublished\":\"2019-05-17T12:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/\"},\"wordCount\":243,\"commentCount\":0,\"articleSection\":[\"Pressmeddelande\"],\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/\",\"url\":\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/\",\"name\":\"IRLAB genomf\u00f6r aktiesplit - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2019-05-17T12:45:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IRLAB genomf\u00f6r aktiesplit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB genomf\u00f6r aktiesplit - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB genomf\u00f6r aktiesplit - IRLAB","og_description":"Vid IRLAB Therapeutics AB:s \u00e5rsst\u00e4mma den 25 april 2019 beslutades om en uppdelning av bolagets aktie, en s\u00e5 kallad aktiesplit. De beslutade villkoren f\u00f6r aktiespliten \u00e4r en 5:1 uppdelning, d\u00e4r varje nuvarande aktie (1) delas upp i fem (5) aktier av samma slag. Datum f\u00f6r genomf\u00f6randet av uppdelningen har nu fastst\u00e4llts.","og_url":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/","og_site_name":"IRLAB","article_published_time":"2019-05-17T12:45:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#article","isPartOf":{"@id":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/"},"author":{"name":"","@id":""},"headline":"IRLAB genomf\u00f6r aktiesplit","datePublished":"2019-05-17T12:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/"},"wordCount":243,"commentCount":0,"articleSection":["Pressmeddelande"],"inLanguage":"sv-SE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/","url":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/","name":"IRLAB genomf\u00f6r aktiesplit - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2019-05-17T12:45:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/irlab-genomfor-aktiesplit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"IRLAB genomf\u00f6r aktiesplit"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/2995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=2995"}],"version-history":[{"count":0,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/2995\/revisions"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=2995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/categories?post=2995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/tags?post=2995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}